MK 8389

Drug Profile

MK 8389

Alternative Names: MK-8389

Latest Information Update: 04 Feb 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class Small molecules
  • Mechanism of Action Follicle stimulating hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Infertility

Most Recent Events

  • 05 Jan 2016 Merck completes a phase-I trial in infertility in the Netherlands (EudraCT2010-022396-57)
  • 05 Jan 2016 Efficacy and adverse events data from a phase-I trial in infertility released by Merck
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top